All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal solid tumors, with a 5-year survival rate of less than 6% \[[@pone.0173960.ref001], [@pone.0173960.ref002]\]. Although most patients with locally advanced or metastatic PDAC die within 5 years, a few patients with localized PDAC can achieve long-term survival, if complete resection and adjuvant treatment can be administered \[[@pone.0173960.ref003], [@pone.0173960.ref004]\]. Adjuvant treatment is mandatory because it more than doubles the 5-year survival rate, from approximately 10% with surgery alone to 25% with adjuvant chemotherapy following surgery \[[@pone.0173960.ref005]--[@pone.0173960.ref010]\]. However, the appropriate time to initiate adjuvant treatment, considering patient' safety, compliance and effectiveness, has not been well described in PDAC patients to date.

Recent retrospective data from the ESPAC-3 study found that completion of six cycles of chemotherapy was independently associated with longer survival \[[@pone.0173960.ref011]\]. Furthermore, early chemotherapy initiation would be more harmful than delayed initiation of chemotherapy in patients with incomplete scheduled chemotherapy. Therefore, they suggested that chemotherapy should be considered after adequate recovery. However, theoretically, micrometastatic deposits are eliminated more effectively with earlier chemotherapy administration, thereby reducing early recurrence \[[@pone.0173960.ref012]\]. Moreover, there is evidence that early adjuvant treatment initiation leads to superior survival rates for patients with breast \[[@pone.0173960.ref013], [@pone.0173960.ref014]\], colorectal \[[@pone.0173960.ref015]--[@pone.0173960.ref017]\], and pancreatic cancer \[[@pone.0173960.ref012], [@pone.0173960.ref018]\]. Thus, the National Comprehensive Cancer Network (NCCN) guidelines state that chemotherapy should be initiated for all patients who underwent curative resection, but they do not specify the optimal start time for chemotherapy or whether it should be delayed until full recovery \[[@pone.0173960.ref019]\]. In clinical trials and practice, most patients received adjuvant treatment within 4--8 weeks unless postoperative complications occurred, and there is an apparent disagreement in the appropriate time to receive adjuvant treatment between guidelines (within 3 months) and clinical trials (within 4--8 weeks) \[[@pone.0173960.ref005]--[@pone.0173960.ref010]\].

The current study evaluated whether early initiation of adjuvant treatment could yield better outcomes than delayed initiation in patients with resected PDAC and to determine the importance of scheduled treatment completion.

Patients and methods {#sec006}
====================

Patients {#sec007}
--------

Data were obtained from 262 consecutive patients with PDAC who underwent curative resection at Seoul National University Bundang Hospital (Seongnam, Korea) between January 2006 and May 2015. Since 2010, adjuvant treatment has been done universally \[[@pone.0173960.ref005]--[@pone.0173960.ref008]\]. After excluding 149 patients for prior chemotherapy, multiple active primary cancer, follow-up loss, mortality or recurrence within 3 months after surgical resection, and surgery without adjuvant treatment, 113 patients who underwent curative surgical resection followed by adjuvant treatment were enrolled retrospectively. According to the median time of adjuvant treatment initiation (TT), enrolled patients were divided into early and delayed groups ([Fig 1](#pone.0173960.g001){ref-type="fig"}). The study protocol was reviewed and approved by the Institutional Review Board (IRB) of Seoul National University Bundang Hospital (IRB no.: B-1605-349-101). Our institutional review board waived the need for written informed consent from the participants.

![Patient flow diagram.\
Enrolled patients were divided into early and delayed groups, according to the median time of adjuvant treatment initiation.](pone.0173960.g001){#pone.0173960.g001}

Outcomes {#sec008}
--------

The outcomes for this study were overall survival (OS) and disease-free survival (DFS) in both groups. OS was defined as the time from the date of surgery to the date of death. DFS was defined as the time from the date of surgery to the date of the first documentation of recurrence or death, if either event occurred before documented radiological or histological recurrence. Patients alive without recurrence were censored on the date of the last follow-up.

Data collection, postoperative management, and surveillance {#sec009}
-----------------------------------------------------------

Patient characteristics included age, sex, comorbidities, and preoperative laboratory exam results. Additionally, surgical data, pathologic data, strategy and regimens of adjuvant treatment, TT, postoperative complications, and postoperative recurrence or mortality were collected. Comorbidities were assessed by the Charlson age-adjusted comorbidity index (CACI) \[[@pone.0173960.ref020], [@pone.0173960.ref021]\]. All patients underwent contrast-enhanced abdominal-pelvic computed tomography (CT) to evaluate postoperative complications within 4 weeks. Postoperative complications were defined as events that required additional treatment within 3 months of surgery, based on the Clavien-Dindo classification \[[@pone.0173960.ref022], [@pone.0173960.ref023]\]. Grade III--IV complications were defined as major if they required surgical, endoscopic, or radiological intervention, regardless of organ dysfunction. After wound healing, patients received adjuvant chemotherapy and/or concurrent chemoradiotherapy within 3 months of surgery. Gemcitabine alone, 5-fluorouracil (FU) plus leucovorin, or concurrent chemoradiotherapy (gemcitabine, 5-FU, or capecitabine-based chemoradiotherapy) was used as adjuvant treatment for most patients \[[@pone.0173960.ref005], [@pone.0173960.ref007]--[@pone.0173960.ref010], [@pone.0173960.ref019]\]. Most patients underwent laboratory tests and contrast-enhanced abdominal-pelvic CT every 8--12 weeks for the first 2 years. If patients had no apparent recurrence during that time, they were then followed at 6-month intervals \[[@pone.0173960.ref019]\]. If documented radiological or histological recurrence occurred, patients received palliative chemotherapy or the best supportive care. Various regimens, such as FOLFIRINOX, FOLFOX, XELOX, gemcitabine alone, gemcitabine plus erlotinib, gemcitabine plus cisplatin, and capecitabine, were used as first-line palliative chemotherapeutic regimens.

Statistical analysis {#sec010}
--------------------

Differences in continuous and non-continuous variables between the early and delayed groups were compared using Student's t-test and χ^2^ tests, respectively. Kaplan-Meier analysis was used to generate survival curves and calculate median survival times, which were compared using the log-rank test. The risk of death or recurrence was compared using the log-rank test and the Cox proportional hazards regression model. Risks are expressed as hazard ratios (HRs). Among the clinical variables included in univariate analyses, those with a two-sided P-value \<0.05 were chosen for multivariate analyses with stepwise selection. A two-sided P-value \<0.05 was considered statistically significant. All statistical analyses were performed using STATA 14.0 software (STATA Corp., College Station, TX).

Results {#sec011}
=======

Patient characteristics {#sec012}
-----------------------

Among 262 who had undergone potentially curative resection, 46 patients were excluded due to prior chemotherapy, synchronous malignancies, follow-up loss and early mortality or recurrence (\<3 months), and 103 patients who did not receive adequate adjuvant treatment due to delayed postoperative recovery (poor performance) or patients' decision were excluded as well ([Fig 1](#pone.0173960.g001){ref-type="fig"}). For the 113 patients (chemotherapy alone, 70 \[61.9%\]; concurrent chemoradiotherapy, 43 \[38.1%\]), the median TT was 35 days (range, 20--83 days). In total, 71 patients (62.8%) completed six cycles of adjuvant treatment. Fifty-six patients were in the early group (TT \<35 days), and 57 patients were in the delayed group (TT ≥35 days) ([Fig 1](#pone.0173960.g001){ref-type="fig"} and [S1 Fig](#pone.0173960.s003){ref-type="supplementary-material"}). The median TTs were 28 days in the early group and 42 days in the delayed group. Most patients (104/113, 92.0%) received adjuvant treatment within 8 weeks.

Patient baseline characteristics were comparable in both groups in terms of age, sex, comorbidity index, surgical data, pathologic features, and adjuvant treatment, with the exception of grade III--IV postoperative complications (5.4% in the early group vs. 22.8% in the delayed group) ([Table 1](#pone.0173960.t001){ref-type="table"}).

10.1371/journal.pone.0173960.t001

###### Patient baseline characteristics.

![](pone.0173960.t001){#pone.0173960.t001g}

  Characteristic, no. (%)             Timing of the adjuvant treatment                       
  ----------------------------------- ---------------------------------- ------------------- -------
  No. of patients                     56                                 57                  
  Age, median (range), years          60 (38--80)                        66 (43--77)         0.148
  Sex                                                                                        0.746
   Female                             19 (33.9)                          21 (36.8)           
   Male                               37 (66.1)                          36 (63.2)           
  CACI                                                                                       0.662
   \<6                                54 (96.4)                          54 (94.7)           
   ≥6                                 2 (3.6)                            3 (5.3)             
  Preoperative CA19-9                                                                        0.774
   ≤100 U/mL                          27 (47.3)                          29 (50.0)           
   \>100 U/mL                         29 (52.7)                          28 (50.0)           
  Time of surgery                                                                            0.112
   2006--2009 year                    8 (14.3)                           15 (26.3)           
   2010--2015 year                    48 (85.7)                          42 (73.7)           
  Surgical procedure                                                                         0.333
   Laparoscopic resection             14 (25.0)                          10 (17.5)           
   Open resection                     42 (75.0)                          47 (82.5)           
  Type of resection                                                                          0.383
   DP                                 20 (35.7)                          16 (28.1)           
   PD                                 36 (64.3)                          41 (71.9)           
  Operating time                                                                             0.844
   ≤500 minutes                       46 (82.1)                          46 (80.7)           
   \>500 minutes                      10 (17.9)                          11 (19.3)           
  Intraoperative transfusion                                                                 0.346
   No                                 48 (85.7)                          45 (78.9)           
   Yes                                8 (14.3)                           12 (21.1)           
  Longest diameter of primary tumor                                                          0.194
   ≤2 cm                              12 (21.4)                          7 (12.3)            
   \>2 cm                             44 (78.6)                          50 (87.7)           
  Nodal status                                                                               0.153
   Negative                           25 (44.6)                          18 (31.6)           
   Positive                           31 (55.4)                          39 (68.4)           
  Resection margin status                                                                    0.653
   R0                                 47 (83.9)                          46 (80.7)           
   R1                                 9 (16.1)                           11 (19.3)           
  Differentiation                                                                            0.999
   Well                               5 (8.9)                            5 (8.8)             
   Moderate                           44 (78.6)                          45 (78.9)           
   Poor                               7 (12.5)                           7 (12.3)            
  Angiolymphatic invasion                                                                    0.159
   Negative                           31 (55.4)                          24 (42.1)           
   Positive                           25 (44.6)                          33 (57.9)           
  Venous invasion                                                                            0.911
   Negative                           33 (58.9)                          33 (57.9)           
   Positive                           23 (41.1)                          24 (42.1)           
  Perineural invasion                                                                        0.592
   Negative                           6 (10.7)                           8 (14.0)            
   Positive                           50 (89.3)                          49 (86.0)           
  Postoperative complications                                                                0.024
   No                                 38 (67.9)                          29 (50.9)           
   Grade I/II                         15 (26.8)                          15 (26.3)           
   Grade III/IV                       3 (5.4)                            13 (22.8)           
  Adjuvant treatment                                                                         0.153
   Chemotherapy alone                 31 (55.4)                          39 (68.4)           
   Concurrent chemoradiotherapy       25 (44.6)                          18 (31.6)           
  Completed 6 cycles of treatment                                                            0.273
   Yes                                38 (67.9)                          33 (57.9)           
   No                                 18 (32.1)                          24 (42.1)           
  Median follow-up, months (range)    23.5 (7.0--119.7)                  16.5 (5.8--114.4)   0.230

CACI, Charlson age-adjusted comorbidity index; CA19-9, carbohydrate antigen 19--9; DP, distal pancreatectomy; PD, pancreaticoduodenectomy; R0, macroscopically and microscopically negative resection margin; R1, microscopically positive resection margin.

OS and DFS in the early and delayed groups {#sec013}
------------------------------------------

The median OS and DFS times for the overall study population were 29.5 and 14.7 months, respectively, during the median 20.3-month follow-up. The early group had a significantly longer OS than the delayed group (39.1 vs. 21.1 months, P = 0.018), and a longer DFS than the delayed group (18.8 vs. 10.0 months, P = 0.034) ([Fig 2](#pone.0173960.g002){ref-type="fig"}). Additionally, of the 104 patients receiving adjuvant treatment within 8 weeks, patients who received earlier treatment (TT \<33 days) had significantly longer OS and DFS than those who did not (TT ≥33 days) (P = 0.043 and = 0.005, respectively) ([S2 Fig](#pone.0173960.s004){ref-type="supplementary-material"}). By multivariate Cox regression analysis, lack of adjuvant treatment completion, delayed adjuvant treatment initiation, and positive angiolymphatic invasion were independent prognostic factors for OS and DFS ([Table 2](#pone.0173960.t002){ref-type="table"} and [S1 Table](#pone.0173960.s001){ref-type="supplementary-material"}). There were no significant differences in the reasons for discontinuing adjuvant treatment between early and delayed groups ([S2 Table](#pone.0173960.s002){ref-type="supplementary-material"}).

10.1371/journal.pone.0173960.t002

###### Risk factors for overall survival.

![](pone.0173960.t002){#pone.0173960.t002g}

  Risk factor                         No.   Univariate analysis    Multivariate analysis                          
  ----------------------------------- ----- ---------------------- ----------------------- ---------------------- ---------
  Timing of the adjuvant treatment                                                                                
   Early initiation                   56                                                                          
   Delayed initiation                 57    1.880 (1.107--3.191)   0.019                   1.822 (1.081--3.070)   0.024
  Age, years                                                                                                      
   ≤65                                65                                                                          
   \>65                               48    0.698 (0.398--1.224)   0.698                                          
  Sex                                                                                                             
   Female                             40                                                                          
   Male                               73    1.544 (0.861--2.770)   0.145                                          
  CACI                                                                                                            
   \<6                                108                                                                         
   ≥6                                 5     1.541 (0.372--6.380)   0.551                                          
  Preoperative CA19-9                                                                                             
   ≤100 U/mL                          56                                                                          
   \>100 U/mL                         57    1.315 (0.776--2.229)   0.309                                          
  Time of surgery                                                                                                 
   2006--2009 year                    23                                                                          
   2010--2015 year                    90    1.037 (0.588--1.828)   0.901                                          
  Surgical procedure                                                                                              
   Laparoscopic resection             24                                                                          
   Open resection                     89    2.342 (0.934--5.872)   0.070                                          
  Type of resection                                                                                               
   DP                                 36                                                                          
   PD                                 77    1.058 (0.611--1.831)   0.841                                          
  Operating time                                                                                                  
   ≤500 minutes                       92                                                                          
   \>500 minutes                      21    2.472 (1.343--4.553)   0.004                   1.357 (0.696--2.645)   0.371
  Intraoperative transfusion                                                                                      
   No                                 93                                                                          
   Yes                                20    1.577 (0.852--2.917)   0.147                                          
  Longest diameter of primary tumor                                                                               
   ≤2 cm                              19                                                                          
   \>2 cm                             94    1.849 (0.837--4.083)   0.128                                          
  Nodal status                                                                                                    
   Negative                           43                                                                          
   Positive                           70    2.062 (1.166--3.647)   0.013                   1.675 (0.934--3.003)   0.083
  Resection margin status                                                                                         
   R0                                 93                                                                          
   R1                                 20    1.168 (0.589--2.315)   0.657                                          
  Differentiation                                                                                                 
   Well or moderate                   99                                                                          
   Poor                               14    0.769 (0.329--1.795)   0.543                                          
  Angiolymphatic invasion                                                                                         
   Negative                           55                                                                          
   Positive                           58    1.866 (1.103--3.157)   0.020                   2.116 (1.160--3.862)   0.015
  Venous invasion                                                                                                 
   Negative                           66                                                                          
   Positive                           47    1.837 (1.085--3.109)   0.024                   0.961 (0.519--1.782)   0.961
  Perineural invasion                                                                                             
   Negative                           14                                                                          
   Positive                           99    2.155 (0.858--5.409)   0.102                                          
  Postoperative complications                                                                                     
   No                                 67                                                                          
   Grade I/II                         30    1.107 (0.593--2.069)   0.749                                          
   Grade III/IV                       16    1.537 (0.734--3.219)   0.254                                          
  Completed 6 cycles of treatment                                                                                 
   Yes                                71                                                                          
   No                                 42    4.040 (2.375--6.873)   \<0.001                 4.039 (2.334--6.992)   \<0.001

HR, hazard ratio; CI, confidence interval; CACI, Charlson age-adjusted comorbidity index; CA19-9, carbohydrate antigen 19--9; DP, distal pancreatectomy; PD, pancreaticoduodenectomy; R0, macroscopically and microscopically negative resection margin; R1, microscopically positive resection margin.

![Kaplan-Meier curves of overall survival (A) and disease-free survival (B).\
The early group consisted of patients who received early initiation of adjuvant treatment (\<35 days), and the delayed group consisted of patients who received delayed initiation of adjuvant treatment (≥35 days).](pone.0173960.g002){#pone.0173960.g002}

Survival analyses were conducted by analyzing the survival interval both from the date of surgery and from the date of adjuvant treatment initiation; to avoid lead-time bias. As expected, both OS and DFS were longer in the early group than in the delayed group ([Fig 3](#pone.0173960.g003){ref-type="fig"}).

![Kaplan-Meier curves of overall survival (A) and disease-free survival (B) based on the starting point of the survival interval (date of adjuvant treatment).](pone.0173960.g003){#pone.0173960.g003}

OS and DFS in patients according to planned treatment completion {#sec014}
----------------------------------------------------------------

OS and DFS times were compared between patients who received all six cycles of planned treatment and those who did not ([Fig 4](#pone.0173960.g004){ref-type="fig"}). The former group had a significantly longer OS (42.8 vs. 15.5 months, P \<0.001), and DFS (19.6 vs. 7.1 months, P \<0.001) than the latter group. In the 71 patients who completed planned adjuvant treatment, TT did not influence OS and DFS significantly, although the patients who received early treatment tended to have a longer OS and DFS than those who did not ([Fig 4](#pone.0173960.g004){ref-type="fig"}).

![Kaplan-Meier curves of overall survival (A) and disease-free survival (B) in patients who received all six planned cycles of treatment and those who did not.\
There was no difference in overall or disease-free survival for patients who received all six planned cycles of therapy (P = 0.129 and = 0.195, respectively) and those who did not (P = 0.206 and = 0.133, respectively).](pone.0173960.g004){#pone.0173960.g004}

Given the observed correlation between postoperative complications and delayed adjuvant treatment initiation, survival analysis was conducted for complication-dichotomized groups. As shown in [Fig 5](#pone.0173960.g005){ref-type="fig"}, early initiation compared with delayed initiation of adjuvant treatment was significantly associated with a superior survival rate for patients without postoperative complications, while no significant association was noted for those with complications. Additionally, there was no survival difference between patients who received chemotherapy and those who received chemoradiotherapy as adjuvant treatment ([S3 Fig](#pone.0173960.s005){ref-type="supplementary-material"}).

![The effect of time to adjuvant treatment initiation on overall survival (A, C) and disease-free survival (B, D) in patients without or with postoperative complications, respectively.](pone.0173960.g005){#pone.0173960.g005}

Discussion {#sec015}
==========

Adjuvant treatment is mandatory in patients who undergo curative resection of PDAC. However, previously published data do not specifically indicate how late adjuvant treatment could be delayed without a decrease in efficacy or how early it could be delivered without a decrease in compliance. We evaluated whether or not patients with resected PDAC who received early adjuvant treatment could expect better clinical outcomes than patients who received delayed treatment. For patients who began adjuvant treatment earlier (within 5 weeks after surgery), OS and DFS were increased without a compliance decrease (completion rate: 67.9% in the early group vs. 57.9% in the delayed group). Moreover, the patients who received early treatment and completed all six cycles of treatment tended to have a longer OS and DFS than those who did not, although it did not reach statistical significance.

Although surgery is the gold standard for management of localized PDAC, some experimental evidence suggests that surgery could have some disadvantages in terms of tumor biology, such as stimulation of growth factor release and suppression of cytotoxic T-cell and natural killer cell activation \[[@pone.0173960.ref024]--[@pone.0173960.ref028]\]. This may lead to angiogenesis, accelerated micrometastasis, or activation of occult metastatic tumor cells \[[@pone.0173960.ref029]\]. Thus, the rationale for adjuvant treatment includes the prevention of micrometastasis, especially for pancreatic cancer, which is characterized by early micrometastasis and aggressiveness. A recent study showed that the numbers of primary and metastatic tumor cells were inversely proportional to the time between surgery and the initiation of adjuvant treatment \[[@pone.0173960.ref012]\]. Furthermore, the authors showed that earlier initiation of adjuvant treatment was associated with proportionally longer survival due to a reduction the number of tumor cells \[[@pone.0173960.ref012]\]. As long as patients are fully recovered, theoretically, early initiation of adjuvant treatment should provide better results. From another standpoint, we were concerned that the early initiation of adjuvant treatment is not always beneficial because pancreaticoduodenectomy is a highly morbid surgery with a high complication rate, and patients require a longer time to recover. In the current study, most patients (92.0%) received adjuvant treatment within 8 weeks after full recovery, and 62.8% patients (67.9% in the early group vs. 57.9% in the delayed group) completed the planned six cycles of adjuvant treatment although patients with postoperative complications tended to receive adjuvant treatment later. This result shows that adjuvant treatment could be delivered without a decrease in compliance despite a short TT of less than 5 weeks.

According to previous data from the ESPAC-3 study, most patients with resected PDAC might not fully recover from the pancreatic cancer surgery within 8 weeks, and those patients were predicted to be at a disadvantage because they could not complete the planned six cycles of adjuvant treatment \[[@pone.0173960.ref011]\]. However, the '8 weeks' is quite different from our median TT '5 weeks' and most patients (92.0%) received adjuvant treatment within 8 weeks in the current study. However, earlier start of adjuvant treatment in our study could lower completion rate compared with ESPAC-3 study (67.9% vs. 73% in the early group; 57.9% vs. 67% in the delayed group). Additionally, the current study did further evaluate outcomes according to the postoperative complications. In patients without postoperative complications, the earlier initiation could provide better OS and DFS. Based on our observations and previous *in vivo* & *in vitro* data \[[@pone.0173960.ref012]\], we believe that earlier adjuvant treatment initiation would provide better outcomes, as long as patients are fully recovered.

There were some limitations to the current study. First, the current study was a retrospective study that examined a relatively small number of patients. However, both groups were well balanced and had comparable baseline characteristics. A prospective study would be difficult to perform because of ethical considerations. Secondly, approximately one-third of all patients received adjuvant chemoradiotherapy.

Conclusions {#sec016}
===========

We demonstrated that earlier adjuvant treatment initiation and treatment completion were associated with better survival rates in patients with resected PDAC, although completion of the scheduled treatment was the strongest prognostic factor. Furthermore, earlier adjuvant treatment initiation should be considered, as long as patients have good performance status. Therefore, we suggest that adjuvant treatment be delivered earlier and completed for better outcomes in patients with resected PDAC.
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